TScan Therapeutics (TCRX) Competitors $1.44 +0.14 (+10.77%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.42 -0.01 (-1.04%) As of 04/17/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRX vs. MREO, BNTC, AURA, CYRX, RNAC, TSVT, AQST, TSHA, ATXS, and ATYRShould you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Mereo BioPharma Group (MREO), Benitec Biopharma (BNTC), Aura Biosciences (AURA), Cryoport (CYRX), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Aquestive Therapeutics (AQST), Taysha Gene Therapies (TSHA), Astria Therapeutics (ATXS), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. TScan Therapeutics vs. Mereo BioPharma Group Benitec Biopharma Aura Biosciences Cryoport Cartesian Therapeutics 2seventy bio Aquestive Therapeutics Taysha Gene Therapies Astria Therapeutics Atyr PHARMA TScan Therapeutics (NASDAQ:TCRX) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability. Does the media prefer TCRX or MREO? In the previous week, Mereo BioPharma Group had 3 more articles in the media than TScan Therapeutics. MarketBeat recorded 4 mentions for Mereo BioPharma Group and 1 mentions for TScan Therapeutics. Mereo BioPharma Group's average media sentiment score of 0.73 beat TScan Therapeutics' score of 0.63 indicating that Mereo BioPharma Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mereo BioPharma Group 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TCRX or MREO more profitable? Mereo BioPharma Group has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,188.88%. Mereo BioPharma Group's return on equity of 0.00% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TScan Therapeutics-1,188.88% -58.72% -36.02% Mereo BioPharma Group N/A N/A N/A Do analysts prefer TCRX or MREO? TScan Therapeutics presently has a consensus price target of $9.33, indicating a potential upside of 548.15%. Mereo BioPharma Group has a consensus price target of $7.71, indicating a potential upside of 235.40%. Given TScan Therapeutics' higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Mereo BioPharma Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Do insiders & institutionals believe in TCRX or MREO? 82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 2.8% of TScan Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation & earnings, TCRX or MREO? Mereo BioPharma Group has lower revenue, but higher earnings than TScan Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTScan Therapeutics$2.82M28.94-$89.22M-$1.15-1.25Mereo BioPharma Group$1M356.84-$29.47M-$0.06-38.33 Which has more risk & volatility, TCRX or MREO? TScan Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Does the MarketBeat Community prefer TCRX or MREO? Mereo BioPharma Group received 12 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 83.67% of users gave TScan Therapeutics an outperform vote while only 80.30% of users gave Mereo BioPharma Group an outperform vote. CompanyUnderperformOutperformTScan TherapeuticsOutperform Votes4183.67% Underperform Votes816.33%Mereo BioPharma GroupOutperform Votes5380.30% Underperform Votes1319.70% SummaryMereo BioPharma Group beats TScan Therapeutics on 12 of the 18 factors compared between the two stocks. Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition Export to ExcelMetricTScan TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.49M$2.84B$5.30B$7.35BDividend YieldN/A1.90%5.12%4.31%P/E Ratio-1.3630.4821.7117.77Price / Sales28.94441.91379.3997.68Price / CashN/A168.6838.2234.64Price / Book0.463.466.443.98Net Income-$89.22M-$72.06M$3.21B$247.44M7 Day Performance27.43%6.38%5.24%4.44%1 Month Performance-7.10%-17.51%-9.49%-7.73%1 Year Performance-78.67%-27.84%11.01%1.28% TScan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics2.856 of 5 stars$1.44+10.8%$9.33+548.1%-78.7%$81.49M$2.82M-1.36100High Trading VolumeMREOMereo BioPharma Group1.8594 of 5 stars$1.83-8.0%$7.71+321.5%-10.9%$283.92M$1M-30.5040High Trading VolumeBNTCBenitec Biopharma2.2245 of 5 stars$12.02-2.4%$24.43+103.2%+186.5%$281.88M$80,000.00-7.9620Short Interest ↑AURAAura Biosciences1.8345 of 5 stars$5.52+1.7%$22.75+312.1%-23.8%$277.24MN/A-3.1950Short Interest ↑CYRXCryoport2.5064 of 5 stars$5.49+2.8%$11.83+115.5%-66.9%$274.01M$228.39M-1.621,020Analyst ForecastRNACCartesian Therapeutics1.7207 of 5 stars$10.11+1.1%$42.14+316.8%-43.2%$261.92M$38.91M-0.1964TSVT2seventy bio1.9348 of 5 stars$4.95flat$6.67+34.7%-1.6%$259.07M$37.86M-2.66440Short Interest ↓High Trading VolumeAQSTAquestive Therapeutics1.8191 of 5 stars$2.62-3.3%$10.57+303.5%-36.0%$259.04M$57.56M-5.82160Positive NewsTSHATaysha Gene Therapies2.6728 of 5 stars$1.24+1.6%$6.63+434.3%-49.4%$254.20M$8.33M1.97180ATXSAstria Therapeutics2.4671 of 5 stars$4.50-3.4%$26.60+491.1%-61.7%$253.95MN/A-2.1530Gap DownATYRAtyr PHARMA2.5929 of 5 stars$2.85+8.8%$18.60+552.6%N/A$253.25M$235,000.00-3.0353Positive News Related Companies and Tools Related Companies Mereo BioPharma Group Competitors Benitec Biopharma Competitors Aura Biosciences Competitors Cryoport Competitors Cartesian Therapeutics Competitors 2seventy bio Competitors Aquestive Therapeutics Competitors Taysha Gene Therapies Competitors Astria Therapeutics Competitors Atyr PHARMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TCRX Stock Free TCRX Stock Alerts